Current partner codePEPTIDESDE
NCT07272837·Not applicable·OBSERVATIONAL

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

Status

Recruiting

Phase

Not applicable

Enrollment

50

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.

Interventions

Treatment arms and agents.

No intervention details reported.

Timeline

From registration to results.

  1. First posted

    Dec 9, 2025

  2. Study start

    May 15, 2026

  3. Primary completion

    Dec 31, 2027

  4. Study completion

    Apr 30, 2028

  5. Results posted

    Not reported

  6. Registry updated

    Jul 17, 2026

Outcomes

What the study measures.

Primary outcomes

Changes in skeletal and cardiac muscle mass

Time frame · 12 months

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
80 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Adults 18-80 years of age * Starting semaglutide for type 2 diabetes or weight loss * Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment) Exclusion Criteria: * Current use of semaglutide for more than 2 weeks * Major recent heart issues or other severe health conditions * Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia) * Dependence on a mobility aid (unable to participate in exercise MRI)

Study locations

1 registered sites.

Canada. Showing up to 24 locations stored in the fast local snapshot.

Mazankowski Alberta Heart Institute

Edmonton, Alberta, Canada

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Semaglutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.